Case Reports in Hematology最新文献

High-Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib-Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition. 高风险慢性淋巴细胞白血病并发伊马替尼治疗的慢性髓性白血病：使用双重酪氨酸激酶抑制剂成功控制病情。

IF 0.7

Case Reports in Hematology Pub Date : 2024-11-15 eCollection Date: 2024-01-01 DOI: 10.1155/2024/1813512

Daniel James, Simone Green, Stefano Molica, David Allsup

引用次数: 0

Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With a Germline DDX41 Mutation. 同种异体造血干细胞移植治疗带有种系 DDX41 基因突变的急性髓性白血病

IF 0.7

Case Reports in Hematology Pub Date : 2024-11-01 eCollection Date: 2024-01-01 DOI: 10.1155/2024/4611649

Shuro Yoshida, Yuichiro Semba, Shuichiro Takashima, Masanori Kadowaki, Ken Takase, Takahiro Maeda, Koichi Akashi, Hiromi Iwasaki

{"title":"Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With a Germline DDX41 Mutation.","authors":"Shuro Yoshida, Yuichiro Semba, Shuichiro Takashima, Masanori Kadowaki, Ken Takase, Takahiro Maeda, Koichi Akashi, Hiromi Iwasaki","doi":"10.1155/2024/4611649","DOIUrl":"https://doi.org/10.1155/2024/4611649","url":null,"abstract":"According to the 2016 World Health Organization classification, a germline DEAD-box helicase 41 gene (DDX41) mutation with myeloid neoplasms has been newly classified. The clinical course of acute myeloid leukemia (AML) with a germline DDX41 mutation has not yet been clarified. In the early phase, this condition is slowly progressive, the rate of remission induction is high, and the prognosis is good. On the other hand, in the late phase, the gradual relapse rate increases and the ultimate prognosis can be poor. Currently, clear guidance on the indication for allogeneic hematopoietic stem cell transplantation (allogeneic HSCT) for AML with a germline DDX41 mutation has not been yet provided. However, we consider that allogeneic HSCT should be performed in patients who are eligible for allogeneic HSCT for germline DDX41 mutations in AML to overcome poor relapse-free survival, referring to previous relevant papers. We report a 49-year-old patient who had pancytopenia and was finally diagnosed with a germline DDX41 mutation and AML. We decided to perform allogeneic HSCT. On day 68, he was complicated by acute graft versus host disease, gut stage 1, grade II, and was started on prednisolone 0.2 mg/kg. He recovered quickly and has been currently alive without symptoms of graft versus host disease for almost 2 years. Regarding donor search for allogeneic HSCT for AML with a germline DDX41 mutation, it is essential to ensure that the donor must be negative for this mutation when the donor is a family donor. If the related donor has a positive mutation, which can cause the development of donor-derived leukemia, allogeneic HSCT should performed from an unrelated donor.","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2024 ","pages":"4611649"},"PeriodicalIF":0.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11548944/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142630188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Four Cases of Myeloproliferative Disorders Associated With Down Syndrome: Distinguishing ML-DS From TAM-DS: Distinguishing TAM-DS and ML-DS: Report of 4 Cases. 四例与唐氏综合征相关的骨髓增生性疾病：唐氏综合征与骨髓增生性疾病的鉴别：鉴别唐氏综合征与骨髓增生性疾病：四例病例的报告。

IF 0.7

Case Reports in Hematology Pub Date : 2024-10-23 eCollection Date: 2024-01-01 DOI: 10.1155/2024/9962512

Kévin Boumeghar, Sylvie Daliphard, Nimrod Buchbinder, Catherine Boutet, Dominique Penther, Pascaline Etancelin, Julien Bourgain, Gérard Buchonnet, Elsa Bera, Victor Bobée

引用次数: 0

A Case Report of Red Blood Cell Alloimmunization and Delayed Hemolytic Transfusion Reaction in a Patient with an Uncommon Phenotype in Sickle Cell Disease: Review of Diagnosis and Management. 镰状细胞病不常见表型患者的红细胞异体免疫和延迟性溶血性输血反应病例报告：诊断与处理回顾。

IF 0.7

Case Reports in Hematology Pub Date : 2024-09-19 eCollection Date: 2024-01-01 DOI: 10.1155/2024/9980747

Cassandra P Wang, Denise Malicki, Courtney D Thornburg, Sonya Martinez, Jennifer C Yu

{"title":"A Case Report of Red Blood Cell Alloimmunization and Delayed Hemolytic Transfusion Reaction in a Patient with an Uncommon Phenotype in Sickle Cell Disease: Review of Diagnosis and Management.","authors":"Cassandra P Wang, Denise Malicki, Courtney D Thornburg, Sonya Martinez, Jennifer C Yu","doi":"10.1155/2024/9980747","DOIUrl":"https://doi.org/10.1155/2024/9980747","url":null,"abstract":"A delayed hemolytic transfusion reaction (DHTR) is a potential complication for patients with sickle cell disease (SCD) who develop red blood cell (RBC) alloimmunization to foreign antigens from allogeneic transfusions, potentially resulting in life-threatening hemolytic anemia between 24 hours and 28 days after the transfusion. Guidelines have suggested obtaining an extended RBC antigen profile by genotyping in patients with SCD to provide increased accuracy for antigen matching. We present a pediatric patient with SCD and a rare RBC phenotype that was not identified by serology who developed DHTR after her second lifetime transfusion and highlight the potential advantages of molecular genotyping. She was successfully managed by transfusion with \"least incompatible\" packed RBCs and aggressive medical management per American Society of Hematology clinical guidelines. Molecular genotyping is advantageous over serologic phenotyping because it can provide additional antigen information, such as increased accuracy for C antigen determination and Fyb antigen matching. Having RBC genotyping results on file for patients with SCD can facilitate care in two ways-by preventing alloimmunization with potential hemolytic transfusion reaction and by responding rapidly to request rare donors when complicating antibodies arise.","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2024 ","pages":"9980747"},"PeriodicalIF":0.7,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11427715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142356141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

EBV-Positive Classic Hodgkin Lymphoma and Primary Nodal T-Cell/NK-Cell Lymphoma Arising in the Background of Follicular Lymphoma. EBV阳性典型霍奇金淋巴瘤和滤泡性淋巴瘤背景下出现的原发性结节性T细胞/NK细胞淋巴瘤

IF 0.7

Case Reports in Hematology Pub Date : 2024-09-10 eCollection Date: 2024-01-01 DOI: 10.1155/2024/8810646

Suravi Raychaudhuri, Zhao Ming Dong, Scott Knowles, Solomon Graf

引用次数: 0

Pitfalls in Diagnosis: JMML versus KMT2A Rearranged Juvenile AML. 诊断陷阱：JMML与KMT2A重排的青少年急性髓细胞白血病。

IF 0.7

Case Reports in Hematology Pub Date : 2024-09-06 eCollection Date: 2024-01-01 DOI: 10.1155/2024/7151394

Liesbeth Vanheeswijck, Sanjay Tewari, Robin Dowse, Nicola Potter, Jelena Jovanovic, Caroline L Furness, Elsje Van Rijswijk

{"title":"Pitfalls in Diagnosis: JMML versus KMT2A Rearranged Juvenile AML.","authors":"Liesbeth Vanheeswijck, Sanjay Tewari, Robin Dowse, Nicola Potter, Jelena Jovanovic, Caroline L Furness, Elsje Van Rijswijk","doi":"10.1155/2024/7151394","DOIUrl":"https://doi.org/10.1155/2024/7151394","url":null,"abstract":"Background: Lysine methyltransferase 2A (KMT2A) rearrangements are commonly found in juvenile acute myeloid leukaemia (AML). Although distinct diseases, there is a known clinical overlap between KMT2A-rearranged AML and juvenile myelomonocytic leukaemia (JMML). Both occur in infancy or early childhood and present with abnormal monocytosis. Case Report. We report a case of a 20-month-old girl, who presented with lethargy, recurrent infections, bruising, and marked hepatosplenomegaly. JMML was suspected after initial work-up, revealing an abnormal monocytosis without blast excess on immunophenotyping. The additional cytogenetic and molecular diagnostics, revealing a KMT2A rearrangement, was decisive for the confirmation of AML.Conclusion: This case highlights the challenges of diagnosing KMT2A-rearranged monocytic AML and the importance of careful morphological assessment in partnership with cytogenetic and molecular diagnostics to distinguish between KMT2A-rearranged AML and JMML. Moreover, the emerging role of molecular monitoring in AML is highlighted.","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2024 ","pages":"7151394"},"PeriodicalIF":0.7,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11398955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142298291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Rare Case of Richter Transformation to Both Clonally Unrelated and Clonally Related Diffuse Large B-Cell Lymphoma in the Same Patient. 罕见的同一名患者同时发生里氏转化为克隆无关和克隆相关的弥漫大 B 细胞淋巴瘤病例

IF 0.7

Case Reports in Hematology Pub Date : 2024-08-31 eCollection Date: 2024-01-01 DOI: 10.1155/2024/7913296

Michelle D Don, Carlos Casiano, Huan-You Wang, Mikhail Gorbounov, Wei Song, Edward D Ball

引用次数: 0

Isatuximab for Delayed Red Cell Engraftment after Allogeneic Hematopoietic Cell Transplantation. 伊沙妥昔单抗治疗同种异体造血细胞移植后的红细胞移植延迟。

IF 0.7

Case Reports in Hematology Pub Date : 2024-08-30 eCollection Date: 2024-01-01 DOI: 10.1155/2024/5790011

Mary Nauffal, Stephen Eng, Andrew Lin, Alexander Chan, Kathryn Mazzerella, Sergio Giralt, Miguel-Angel Perales, Boglarka Gyurkocza

{"title":"Isatuximab for Delayed Red Cell Engraftment after Allogeneic Hematopoietic Cell Transplantation.","authors":"Mary Nauffal, Stephen Eng, Andrew Lin, Alexander Chan, Kathryn Mazzerella, Sergio Giralt, Miguel-Angel Perales, Boglarka Gyurkocza","doi":"10.1155/2024/5790011","DOIUrl":"10.1155/2024/5790011","url":null,"abstract":"Isatuximab is an IgG1κ-derived monoclonal antibody against CD38 approved for the treatment of adult patients with multiple myeloma. Here we describe the successful treatment of a therapy-refractory pure red cell aplasia case following ABO-mismatched allogeneic stem cell transplantation with isatuximab. Our patient was a 75-year-old female with acute myeloid leukemia who received an HLA-B antigen mismatched, unrelated peripheral blood stem cell transplant with a major ABO incompatibility (blood group A+ in the donor and blood group O+ in the recipient). The patient developed persistent red cell aplasia and anti-A antibodies for more than 500 days from transplant. She received therapy with rituximab, bortezomib, prednisone, and darbepoetin alfa with partial to no response. After repeated insurance denials for daratumumab, isatuximab was obtained from the manufacturer through their CareASSIST program. Following the completion of 2 cycles of isatuximab (8 doses), significant and sustained red cell recovery was observed.","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2024 ","pages":"5790011"},"PeriodicalIF":0.7,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11379505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute Coronary Syndrome as an Unusual Initial Presentation of T-Prolymphocytic Leukemia: A Case Report and Review of the Literature. 急性冠状动脉综合征是 T 淋巴细胞白血病的不寻常初始表现：病例报告和文献综述。

IF 0.7

Case Reports in Hematology Pub Date : 2024-08-27 eCollection Date: 2024-01-01 DOI: 10.1155/2024/4303614

Christian R Klein, Felix Jansen, Peter Brossart, Marco Herling, Georg Feldmann

{"title":"Acute Coronary Syndrome as an Unusual Initial Presentation of T-Prolymphocytic Leukemia: A Case Report and Review of the Literature.","authors":"Christian R Klein, Felix Jansen, Peter Brossart, Marco Herling, Georg Feldmann","doi":"10.1155/2024/4303614","DOIUrl":"10.1155/2024/4303614","url":null,"abstract":"T-prolymphocytic leukaemia (T-PLL) is the most common mature T-cell leukaemia in Central Europe and is often manifested by rapidly increasing lymphocytosis, marked bone marrow infiltration and splenomegaly. In 10-15% of cases, the diagnosis is made by incidental findings in otherwise asymptomatic patients. Here we report a case of T-PLL that initially became symptomatic due to the presence of acute coronary syndrome (ACS). Initially, emergency coronary angiography with consecutive emergency 5-coronary artery bypass grafting (CABG) was performed. Leukocytosis was found perioperatively and T-PLL (with TCL1 rearrangement) was subsequently diagnosed. Despite known potential cardiotoxicity, the patient was treated with the anti-CD52 antibody alemtuzumab with a gradual dose increase from 3 mg to 30 mg per day. Systemic alemtuzumab therapy resulted in the complete remission of T-PLL in the bone marrow without any impairment to cardiac function. The patient was then eligible to undergo a consolidating allogeneic stem cell transplant (alloSCT). The reported case shows that T-PLL can also become initially symptomatic through an acute coronary syndrome on the basis of complex coronary heart disease. Targeted antileukaemic therapy with the monoclonal antibody alemzutumab can lead to effective systemic cytoreduction without cardiac dysfunction even in patients with severe cardiac disease, although cases of cardiotoxicity have been reported.","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2024 ","pages":"4303614"},"PeriodicalIF":0.7,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11371457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142126976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hematologists/Physicians Need to Be Aware of Pseudohypercalcemia in Monoclonal Gammopathy: Lessons from a Case Report. 血液病学家/医生需要警惕单克隆丙种球蛋白病的假性高钙血症：病例报告的启示。

IF 0.7

Case Reports in Hematology Pub Date : 2024-08-19 eCollection Date: 2024-01-01 DOI: 10.1155/2024/8844335

Svenja F B J Mennens, Ellen Van der Spek, Janneke Ruinemans-Koerts, Marcel M G J Van Borren

引用次数: 0